Key result
Transfemoral transcaval TAVI was feasible and safe in high-risk patients, achieving 94% device success and reaching the clinical efficacy endpoint in 88% of patients at 30 days.
Why the study?
Transfemoral transarterial and transaxillary/subclavian approaches for TAVI may not be feasible in all patients, prompting evaluation of the initial European experience with transfemoral transcaval TAVI.
Is transfemoral transcaval TAVI feasible and safe in high-risk patients with severe aortic stenosis not suitable for standard transarterial access?
Observational (n=50)
Yes
Is transfemoral transcaval TAVI feasible and safe in high-risk patients with severe aortic stenosis not suitable for standard transarterial access?
Transfemoral transcaval TAVI is a feasible and safe alternative access route for high-risk patients with severe aortic stenosis who are ineligible for standard transarterial approaches.
May offer an alternative access route for ineligible patients; leaves open the need for randomized trials to confirm outcomes.
No takes yet. Share an insight, caveat, or question.
Costa et al. (2020) conducted an observational in Severe aortic stenosis (n=50). Transfemoral transcaval transcatheter aortic valve implantation (TAVI) was evaluated on Clinical efficacy endpoint at 30 days. Transfemoral transcaval TAVI was feasible and safe in high-risk patients, achieving 94% device success and reaching the clinical efficacy endpoint in 88% of patients at 30 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: